Machado-Joseph disease (MJD) is a fatal dominantly-inherited neurodegenerative disorder associated with an expanded polyglutamine tract within the ataxin-3 protein, and characterized by progressive impairment of motor coordination, associated to neurodegeneration of specific brain regions, including cerebellum and striatum. The currently available therapies do not allow modification of disease progression.
Introduction
Therefore, the first aim of the present study was to evaluate NPY levels in cerebellum of MJD patients and affected brain areas of two genetic MJD mouse models: a cerebellar transgenic mouse model expressing a truncated fragment of mutant ataxin-3 and a striatal lentiviral-based mouse model. Since we observed a decrease of NPY in the analyzed samples, we hypothesized that the increase of NPY in the MJD affected brain areas could have an impact on the progression of the disease. Therefore, taking advantage of adeno-associated viral (AAV) vectors, we evaluated whether NPY overexpression would mitigate the MJD phenotype in the same mouse models of the disease. For the first time, we provide evidence that NPY overexpression was able to significantly alleviate MJD-associated motor deficits and neuropathology, which may be associated to the increase of brain-derived neurotrophic factor (BDNF) and the attenuation on neuroinflammation.
Results

Levels of NPY are reduced in MJD patients and mouse models.
In order to investigate NPY levels in MJD we analyzed human post-mortem tissue and samples from mice models of the disease.
Dentate nucleus extracts of post-mortem brains of two MJD patients revealed a 92-98% reduction of Npy mRNA levels relative to a control sample (Fig. 1A) .
Moreover, cerebellar extracts of 34 week-old MJD Tg animals expressing truncated mutant ataxin-3 with 69 glutamines also displayed a robust significant decrease (*** p<0.001, n=3-4) of Npy mRNA levels, when compared to WT mice (Fig. 1B) . NPY levels in the striatal MJD mouse model, in which lentiviral vectors encoding Atx3MUT were injected in one striatal hemisphere and lentivirus encoding Atx3WT in the other, as control, were also measured. Indeed, Atx3MUT expression significantly decreased (* p<0.05, n=4) the Npy mRNA levels when compared to the Atx3WT transduced hemisphere, 4 weeks post-injection (Fig. 1C) . Furthermore, this depletion was also observed at the protein level ( Fig. 1D and E) , since the number of striatal positive NPYexpressing interneurons in the mutant ataxin-3 transduced hemisphere was significantly reduced (Fig. 1F , 4848 ± 417 versus 5709 ± 374 control, * p<0.05, n=5).
These results show that mutant ataxin-3 expression reduces NPY levels in MJD.
NPY overexpression alleviates balance and motor coordination impairments.
We recently showed that MJD Tg mice display a severe ataxic phenotype (13) .
Since NPY levels are reduced in these animals and neuroprotective roles for NPY have been described (19) (20) (21) (22) (23) (24) (25) (26) (27) , we investigated whether NPY overexpression would improve the MJD phenotype. For that purpose, we injected AAV vectors encoding NPY, or EGFP, as control, in the cerebella of five-week-old Tg mice and WT littermates ( Fig.   2A ), and performed behavioral tests to assess motor coordination and balance before and 4 and 8 weeks post-injection.
Motor coordination and balance were assessed by the stationary rotarod test.
Before stereotaxic surgeries, 5 weeks-old Tg mice displayed a marked phenotype characterized by difficulties walking and equilibrating on the rotating rod when compared to WT littermates, as evidenced by a diminished latency to fall of the rod (Fig. 2B) . At 8 weeks after vectors injection, it became clear that cerebellar NPY overexpression significantly prevented this balance and motor coordination impairment (* p<0.05 relative to Tg+EGFP, n=8-13).
Moreover, in the beam walking test, Tg animals took more time to cross the beams than WT mice. By 8 weeks post-injection, NPY overexpressing animals showed a significant better performance in round beams ( Fig. 2C ; * p<0.05 and *** p<0.001, n=8-13).
The evaluation of Tg mice gait was also helpful to assess the ataxic movement.
The footprint pattern analysis 4 weeks after stereotaxic injection revealed that Tg mice with cerebellar NPY overexpression showed an almost complete rescue of base width enlargement (Fig. 2D, 
NPY overexpression reduces cerebellar neuropathology.
To evaluate whether the phenotypic improvements were due to the prevention of cerebellar neurodegeneration, we compared brains of NPY overexpressing and control Tg mice regarding its size and histopathological parameters, 8 weeks after viral vectors injection.
The injection of AAV-NPY increased NPY-immunoreactivity in most lobules and in deep nuclei of the cerebellum (Fig. 3A and B) . To examine the cerebellar volume relative to the whole brain, cresyl violet-stained cross sectional areas were used for volume extrapolation (Fig. 3C and D) . Tg mice submitted to cerebellar NPY overexpression showed reduced cerebella volume shrinkage (Fig. 3E, * p<0 .05, n=6-8) compared to Tg+EGFP mice. Furthermore, the analysis of cerebellar layers showed that Tg+NPY mice exhibit a larger granular layer thickness (Fig. 3F-H Immunofluorescence labeling of Purkinje cells with an anti-HA antibody, which stains mutant ataxin-3 ( Fig.3I and J) , showed that NPY overexpression promoted a decrease in the number of mutant ataxin-3 aggregates in Purkinje cells, compared to Tg+EGFP mice (Fig. 3K, * p<0.05, n=6-8) .
Overall, these results show that NPY overexpression in the cerebellum of MJD Tg mice preserves cerebellar structure and decreases the number of mutant ataxin-3 aggregates.
NPY overexpression reduces the number of mutant ataxin-3 inclusions.
To further evaluate NPY overexpression positive effects in MJD-associated neuropathology, namely the formation of mutant ataxin-3 aggregates, we used the striatal lentiviral-based rodent model of the disease, a strategy that allows precise, quantitative analysis of neuropathological deficits induced by mutant ataxin-3 expression (10, 13, 14, 16, 28, 29) . Furthermore, this MJD model allows the expression of a full-length mutated ataxin-3 in the striatum, a brain region affected in MJD that is not impaired in the transgenic model. For that we bilaterally co-transduced the striatum of the lentiviral-based mouse model with AAV-NPY or AAV-EGFP, as control (Fig.   4A ). AAV-NPY injection induced a 31-fold increase (** p<0.01, n=4) in Npy mRNA striatal levels (Fig. 4B) promoting a higher striatal NPY-immunoreactivity ( Fig. 4C and   D ) further confirmed by western blot analysis (Fig. 4E ).
NPY overexpression in the MJD striata robustly decreased the number of mutant ataxin-3 neuronal inclusions (Fig. 4G ) when compared to control EGFP co-transduction (Fig. 4F ), either at 4 weeks (19820 ± 4080 versus 123000 ± 29910 control, ** p<0.01, n=4) and at 8 weeks post-injection (19480 ± 3080 versus 120900 ± 19640 control, * p<0.01, n=4; Fig. 4H ). Additionally, a large number of ubiquitin-positive inclusions was observed in the control animals (co-injected with mutant ataxin-3 and EGFP, Fig. 4I ), which were almost absent in the NPY co-transduced striata (Fig. 4J) . The observed reduction of mutant ataxin-3 inclusions induced by NPY overexpression was further confirmed by western blot analysis of the striatal total extracts (Fig. 4K ), which revealed a 75% decrease of immunolabelled mutant ataxin-3 aggregates, at both 4 and 8 weeks post-injection of viral vectors (* p<0.05, n=4, Fig. 4L ), when compared to the control mice. No changes were observed in the soluble mutant ataxin-3 levels between the two experimental groups (Fig. 4M) .
These results show that NPY overexpression prevents the accumulation of mutant ataxin-3 neuronal inclusions in the lentiviral striatal MJD model.
NPY overexpression induces striatal neuroprotection.
To investigate whether NPY overexpression would prevent neuronal dysfunction induced by mutant ataxin-3, we performed immunohistochemical detection of dopamine and cyclic AMP-regulated phosphoprotein 32 (DARPP-32), an intracellular regulator of the dopaminergic signaling (30) . This marker was previously shown to be decreased upon early neuronal dysfunction (10, 16, 29, 31) . Indeed, mutant ataxin-3 expression mediated a striatal functional damage typified by a large volume of DARPP-32 immunoreactivity loss over time ( Fig. 5A and C) , which was reduced by over 55% upon NPY overexpression (Fig. 5B and D It has been previously demonstrated that BDNF levels are decreased in neurodegenerative disorders (32, 33) , and that BDNF overexpression is neuroprotective (34) . To assess whether NPY neuroprotective effects were related to an induction of BDNF up-regulation, we assessed Bdnf mRNA levels in the striatal rodent model of MJD. We found that NPY overexpression mediated a 6.5 times increase of the Bdnf mRNA levels in striata transduced with mutant ataxin-3 (* p<0.05, n=4), 4 weeks postinjection, compared to the control EGFP co-transduction (Fig.6A) . By western blot analysis we also observed an increase of BDNF protein levels (** p<0.01, n=4) in Atx3MUT transduced striata ( 
Discussion
In the present study we showed, for the first time, that NPY levels are decreased in MJD and that NPY overexpression is able to alleviate neuropathology and motor deficits in different MJD mouse models. Since there is no effective therapy able to stop or prevent the progression of the disease, NPY overexpression might be a novel therapeutic candidate strategy for this disorder.
We found that Npy levels were reduced in both postmortem cerebellar extracts of MJD patients and transgenic mice, and also in the striata of the lentiviral-based model. This reduction of NPY levels in MJD is in line with previous reports showing decreased NPY levels in another neurodegenerative disease, namely Alzheimer's disease, in both patients (35, 36) and rodent models (37) . Moreover, this reduction of Npy levels in the striatum is correlated with a reduction in the number of striatal NPY-positive interneurons. Hence, the described cerebellar and striatal neurodegeneration in MJD (4-6) may also affect the NPY-positive neurons, causing the observed decrease of NPY levels.
The transgenic mice used in this study exhibit a pronounced ataxic phenotype as early as 5 weeks of age (13) . NPY overexpression in the cerebellum of these transgenic mice rescued the motor and balance impairments, as assessed by the stationary rotarod, beam walking and footprint analysis. This alleviation of behavioral defects correlated with a reduction of cerebellar disease-related neuropathology, namely a preservation of the cerebellar volume and of the granular layer thickness. Since this transgenic mice express only a c-terminal fragment of mutant ataxin-3, this model may also represent a more general polyQ disease model. Thus, we can hypothesize that NPY overexpression may be neuroprotective in other polyQ diseases. Furthermore, NPY overexpression in the striatal model also mediated neuroprotection typified by a robust decrease in number of mutant ataxin-3 inclusions and reduction of DARPP-32 striatal lesion.
The observed neuroprotective role of NPY is in accordance with previous reports in other paradigms (19, 21, 25) and neurodegenerative diseases (20, 26, 27) , namely in Huntington's disease transgenic mice where an intracerebroventricular injection of NPY reduced their behavioral disabilities and striatal atrophy (27) , and in a rodent model of Parkinson's disease, in which a striatal injection of NPY preserved the nigrostriatal dopaminergic pathway (26) .
To clarify the putative mechanisms through which NPY exerts its protective effects, we investigated its role in promoting BDNF trophic support and antiinflammatory effects. The increase of BDNF levels induced by NPY overexpression may contribute to its neuroprotective effect observed in MJD mouse models. BDNF is a neurotrophic factor and an important pro-survival agent that is depleted in some neurodegenerative diseases, including Huntington's disease (32) and Alzheimer's disease (33) , and its overexpression in the forebrain of an Huntington's disease mouse model prevented the loss of striatal neurons with subsequent rescue of motor phenotype (34) . Moreover, Croce and colleagues showed that NPY was able to decrease amyloid β-peptide toxicity in an in vitro model of Alzheimer's disease, through the up-regulation of BDNF, as a consequence of decreasing the microRNA (miR) 30a-5p (20) , previously shown to down-regulate BDNF (38) . Thus it is possible that NPY exerts neuroprotective effects in MJD by controlling miR expression and hence BDNF levels. On the other hand, the infusion of NPY into the rat hypothalamus leads to increased phosphorylation of CREB, an important transcription factor with multiple targets (39) . Since BDNF and its receptor trkB are CREB-target genes (40), we alternatively hypothesize that NPY overexpression is inducing BDNF up-regulation through a positive regulation of CREB phosphorylation. However, the mechanisms underlying the increase of BDNF induced by NPY overexpression in MJD mouse models should be further investigated.
Since neuroinflammation was previously implicated in MJD pathology (15) (16) (17) , we evaluated the effects of NPY overexpression in this mechanism. Our results underline that NPY overexpression significantly reduced the mRNA levels of proinflammatory cytokine Il6 and prevented mutant ataxin-3 induced increase of microglial immunoreactivity. These results are in accordance with former reports describing an anti-inflammatory-like effect of NPY in a microglia cell line, characterized by the inhibition of IL1β increase and nitric oxide production (24) , and reduction of microglia motility, decreasing the local number of activated microglia (23) .
Furthermore, BDNF also proved to be able to attenuate neuroinflammation, by reducing astrocytosis, microcytosis and proinflammatory cytokines levels (41, 42) . Hence, NPY, directly and/or through the activation of BDNF signaling pathway, restrains the exacerbation of the inflammatory response, preventing the toxic effects of microglia overactivation. This may, at least partially, explain the beneficial effects of NPY overexpression on MJD mouse models.
The present study also showed that NPY overexpression reduced the number of mutant ataxin-3 aggregates without affecting the levels of soluble mutant ataxin-3, in the striatal model, and decreased inclusions in the Purkinje cells, the most severely affected neuronal population in the transgenic model. This reduction of aggregates accumulation suggests that NPY overexpression may activate protein clearance mechanisms, like autophagy, which we previously showed to be impaired both in patients and rodent models of MJD (14) . Since we recently demonstrated the ability of NPY to induce autophagy (22) , autophagy stimulation may be a NPY-induced mechanism responsible for the reduction of mutant ataxin-3 aggregates. However, further studies are needed to characterize NPY effects over autophagy in MJD mouse models. Additionally, since proinflammatory signals may lead to abnormal processing of proteins promoting their aggregation (43, 44) , we hypothesize that NPY overexpression may be indirectly decreasing mutant ataxin-3 aggregation as a result of its actions in reduction of proinflammatory signals.
NPY up-regulation mitigates neuroinflammation through the activation of Y1 receptor (23, 45) , and increases autophagy through the activation of Y1 and Y5 receptors as we recently showed (22) , leading to the hypothesis that the NPY neuroprotective effects in these MJD mouse models might be mediated by these two NPY receptors.
Further studies using specific NPY receptor knock-outs should be taken to assess the role of each NPY receptor in MJD.
In conclusion, this work provides the first evidence that NPY levels are reduced in MJD and that its overexpression mitigates the disease-associated neuropathology and motor-and balance-related deficits. Furthermore, our results suggest that increase of BDNF levels and reduction of neuroinflammation are implicated in the beneficial effects of NPY on MJD pathology. This supports NPY overexpression or administration as a candidate strategy to modulate the abnormal neuropathological and motor changes in MJD.
Materials and methods
Human brain tissue
Post-mortem human brain tissue from dentate nucleus was obtained from University of Groningen, The Netherlands. The tissues included a control patient (male, 68 years) and two MJD patients both females: MJD148 with 70 years and 68 CAG repeats, and MJD176 with 34 years and 77 CAG repeats.
Animals
Young adult male C57BL/6J mice (Charles River, Spain) with five to seven weeks of age were used in this study.
C57Bl/6-background transgenic mouse model expressing the C-terminal-truncated ataxin-3 with 69 glutamine repeats and an N-terminal haemagglutinin (HA) epitope driven by Purkinje-cell-specific L7 promoter were obtained from parallel breeding at our research center (CNC) of a colony of transgenic mice initially obtained from Gunma University Graduate School of Medicine (46) . Genotyping was performed by PCR.
Gender-and age-matched transgenic (Tg) and wild type (WT) littermates at 5 weeks of age were used in this study.
The experiments were carried out in accordance with the European Community directive (2010/63/EU) covering the protection of animals used for scientific purposes.
The researchers received adequate training (FELASA-certified course) and certification to perform the experiments from the Portuguese authorities (Direcção Geral de Alimentação e Veterinária).
Viral vectors production
Lentiviral vectors encoding human wild-type ataxin-3 (Atx3WT) with 27 glutamines or mutant ataxin-3 (Atx3MUT) with 72 glutamines (29) , under the control of phosphoglycerate kinase (PGK) promoter, were produced in HEK-293T cells with a four-plasmid system, as previously described (47) . The lentiviral particles were resuspended in 1% bovine serum albumin in PBS. The viral particle content of batches was determined by assessing HIV-1 p24 antigen levels (RETROtek, Gentaur, France). Viral stocks were stored at -80ºC.
AAV serotype 1/2 vectors, under the control of human synapsin promoter, were kindly provided by Dr. Kugler, from Göttingen University, Germany.
In vivo injection of viral vectors into the striatum and the cerebellum
After anesthesia of the mice with Avertin (280 µg/g, intraperitoneally), viral vectors were stereotaxically injected into the striatum at the following coordinates: anteroposterior +0.6 mm, lateral ±1.8 mm and ventral -3.3 mm, relative to bregma; and into the cerebellum in the following coordinates: anteroposterior -2.3 mm, lateral 0 mm and ventral -3.0 mm, relative to lambda (48) . 
Behavioral assessment
Mice were subjected to locomotor tests before and 4 and 8 weeks after viral vectors injection. Animals were habituated for 1h to a quiet room with controlled temperature and ventilation, dimmed lighting, and handled prior to behavioral testing. Footprint patterns. To obtain footprints, the forepaws and hindpaws of the mice were coated with black and white nontoxic paints, respectively. Mice were allowed to walk on a paper along a 100x10x15 cm runway. A sequence of six consecutive steps was chosen for evaluation, excluding footprints made at the beginning and end of the run where the animal was initiating and finishing movement, respectively. Base width was measured as the average distance between left and right footprints. Overlap between forepaw and hindpaw placement is measured as the distance between the front and hind footprints on each side. The mean of the twelve strides and of the six overlap distance for each animal was considered.
Immunohistochemical procedure
After an overdose of Avertin (2.5 x 280 µg/g intraperitoneally), transcardial perfusion of the mice was performed with PBS followed by fixation with 4%
paraformaldehyde (PFA; Sigma-Aldrich, USA). The brains were removed and postfixed in 4% PFA for 24h and cryoprotected by incubation in 25% sucrose/PBS for 48h.
The brains were frozen and 25 µm coronal sections, for striatal analysis, and 35 µm sagittal sections, for cerebellar analysis, were cut using a cryostat (LEICA CM3050S, Quantitative analysis was performed with a semiautomated image-analysis software package (ImageJ 1.42q software, USA).
Cresyl violet staining
Premounted sagittal sections were stained with cresyl violet (Sigma-Aldrich) for 2 minutes, differentiated in 70% ethanol, dehydrated by passing through 95% ethanol, 100% ethanol and xylene solutions, and mounted onto microscope slides with Eukitt®.
Cell counts of striatal NPY-positive interneurons and mutant ataxin-3 inclusions in striatum and in Purkinje cells
Twelve coronal sections at 200 μm intervals that encompassed the entire region transduced by the viral vectors were scanned with a 20x objective. All striatal NPYpositive interneurons and mutant ataxin-3 inclusions were manually counted, and its number extrapolated for the entire striatum.
Sagittal sections were scanned with a 20x objective. All HA aggregates in Purkinje cells of 8 sections at 280 μm intervals were manually counted and the average number of inclusions was extrapolated to the whole cerebellum.
Evaluation of the DARPP-32 depleted volume and cerebellar volume
The extension of ataxin-3 lesions in the striatum was analysed by photographing, 
Quantification of granular and molecular layers thickness
Lobules V and IX granular and molecular layers thickness was assessed by the mean of three different measures to each layer, in three sections at 280 µm intervals, scanned with a 20x objective. In each image, boundary lines around the granular and the molecular layers were drawn by hand using ImageJ software.
Quantification of Iba-1 immunoreactivity
The immunoreactivity indexes were measured through optic density analysis of the affected striatal regions relative to their corresponding non-affected cortex (defined as background).
Western blot analysis
After an overdose of Avertin, mice were sacrificed by cervical dislocation and 
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). Statistical comparisons were performed using either paired or unpaired Student's t test or 1-way or 2-way ANOVA followed by Bonferroni post-hoc test. Significance thresholds were set at p<0.05, p<0.01 or p<0.001. 
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